FindMyKOL
Clinical trialNCT02614937CompletedPhase 1/PHASE2Interventional

Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion

SponsorOhr Pharmaceutical Inc.Enrollment20Macular EdemaRetinal Vein Occlusion
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This was a prospective, single center, open label, randomized study evaluating the biological effect of squalamine lactate ophthalmic solution, 0.2% combined with intravitreous ranibizumab in patients with macular edema secondary to branch, hemi-central and central retinal vein occlusion (BRVO, HRVO, CRVO).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • John Wroblewski, MD

    Cumberland Valley Retinal Consultants, Hagerstown, MD

    Principal Investigator
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Squalamine Lactate Ophthalmic Solution, 0.2%Ranibizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Apr 2013
Primary completion
31 Dec 2014
Completion
31 Dec 2014
Last update posted
25 Nov 2015
Registered enrollment
20
Registry id
NCT02614937
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.